- Home
- GLUE vs LE Comparison
GLUE vs LE Comparison
Compare GLUE & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- LE
- Stock Information
- Founded
- GLUE 2019
- LE 1963
- Country
- GLUE United States
- LE United States
- Employees
- GLUE N/A
- LE N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- LE Clothing/Shoe/Accessory Stores
- Sector
- GLUE Health Care
- LE Consumer Discretionary
- Exchange
- GLUE Nasdaq
- LE Nasdaq
- Market Cap
- GLUE 283.6M
- LE 280.4M
- IPO Year
- GLUE 2021
- LE N/A
- Fundamental
- Price
- GLUE $5.25
- LE $11.31
- Analyst Decision
- GLUE Buy
- LE Strong Buy
- Analyst Count
- GLUE 2
- LE 1
- Target Price
- GLUE $13.50
- LE $20.00
- AVG Volume (30 Days)
- GLUE 416.3K
- LE 495.3K
- Earning Date
- GLUE 08-07-2025
- LE 09-04-2025
- Dividend Yield
- GLUE N/A
- LE N/A
- EPS Growth
- GLUE N/A
- LE N/A
- EPS
- GLUE 0.08
- LE 0.14
- Revenue
- GLUE $159,487,000.00
- LE $1,338,672,000.00
- Revenue This Year
- GLUE $49.02
- LE $3.31
- Revenue Next Year
- GLUE N/A
- LE $2.34
- P/E Ratio
- GLUE $67.88
- LE $84.20
- Revenue Growth
- GLUE 14889.38
- LE N/A
- 52 Week Low
- GLUE $3.50
- LE $7.65
- 52 Week High
- GLUE $12.40
- LE $19.88
- Technical
- Relative Strength Index (RSI)
- GLUE 65.19
- LE 59.28
- Support Level
- GLUE $5.11
- LE $10.38
- Resistance Level
- GLUE $5.40
- LE $11.45
- Average True Range (ATR)
- GLUE 0.23
- LE 0.81
- MACD
- GLUE 0.05
- LE -0.02
- Stochastic Oscillator
- GLUE 87.24
- LE 34.93
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.